Novartis and SustainAbility presented a webinar on November 27th, the second of a series of conversations about the results and outcomes of Novartis’ 2017 Corporate Responsibility Materiality Assessment.
On this webinar, speakers shared Novartis’ current approach to quantifying and monetizing impact dimensions of their corporate responsibility material issue areas.
John Elkington, Chair of the Impact Valuation Advisory Committee, joined this webinar and set the scene. He embedded Novartis’ impact valuation work into the global context and explored what it will take to strengthen the momentum of monetizing impacts across material issue areas.
This third full materiality assessment for Novartis plays an important role in strengthening the integration of CR in Novartis’ core business. The objectives of the materiality assessment were to:
- Further align strategies with societal expectations, business needs and market developments;
- Intensify dialogue with key stakeholders on a systematic basis;
- Structure and prioritise Novartis’ corporate reporting
